Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough infections after tixagevimab-cilgavimab during community transmission of monoclonal antibody resistant variants

被引：3
|
作者：
Kamboj, Mini [1 ,2 ,3 ,5 ]
Laracy, Justin C. [1 ,2 ,3 ,5 ]
Usiak, Shauna [1 ]
Babady, N. Esther [2 ,4 ]
Yan, Judy [1 ]
Seo, Susan K. [2 ,3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Infect Control, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Infect Dis Serv, New York, NY USA
[3] Weill Cornell Med Coll, Dept Med, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, Clin Microbiol Serv, New York, NY USA
[5] 1275 York Ave, New York, NY 10065 USA
来源：
JOURNAL OF INFECTION | 2023年 / 87卷 / 03期
关键词：
D O I：
10.1016/j.jinf.2023.06.024
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：282 / 285
页数：4
相关论文
共 50 条
  • [1] Efficacy of Preexposure Prophylaxis with Monoclonal Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia
    Benjamini, Ohad
    Tadmor, Tamar
    Avigdor, Abraham
    Gershon, Rotem
    Kliker, Limor
    Fares, Florin
    Atari, Nofar
    Laevsky, Ilana
    Abdelkader, Bayan
    Hod, Tammy
    Golan-Shany, Orit
    Mandelboim, Michal
    Rahav, Galia
    ACTA HAEMATOLOGICA, 2024, 147 (06) : 634 - 645
  • [2] Incidence and Features of SARS-CoV-2 Breakthrough Infection in the Hematological Conditions After Tixagevimab-Cilgavimab Prophylaxis
    Duminuco, Andrea
    Nardo, Antonella
    Orofino, Alessandra
    Giunta, Giuliana
    Conticello, Concetta
    Del Fabro, Vittorio
    Figuera, Amalia
    Chiarenza, Annalisa
    Milone, Giuseppe
    Leotta, Salvatore
    Cupri, Alessandra
    Parisi, Marina
    Mauro, Elisa
    Vetro, Calogero
    Di Raimondo, Francesco
    Romano, Alessandra
    Palumbo, Giuseppe A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S446 - S447
  • [3] Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
    Laracy, Justin C.
    Yan, Judy
    Steiger, Samantha N.
    Tan, Carrie A.
    Cohen, Nina
    V. Robilotti, Elizabeth
    Fender, Jerome
    Cohen, Sara
    Korde, Neha
    Lee-Teh, Melissa
    Noy, Ariela
    Oved, Joseph H.
    Roeker, Lindsey E.
    Shah, Gunjan
    Babady, N. Esther
    Kamboj, Mini
    Seo, Susan K.
    HAEMATOLOGICA, 2023, 108 (11) : 3058 - 3067
  • [4] Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions
    Duminuco, Andrea
    Nardo, Antonella
    Orofino, Alessandra
    Giunta, Giuliana
    Conticello, Concetta
    Del Fabro, Vittorio
    Chiarenza, Annalisa
    Parisi, Marina S.
    Figuera, Amalia
    Leotta, Salvatore
    Milone, Giuseppe
    Cupri, Alessandra
    Cambria, Daniela
    Di Raimondo, Francesco
    Romano, Alessandra
    Palumbo, Giuseppe A.
    CANCER, 2024, 130 (01) : 41 - 50
  • [5] Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
    Stuver, Robert
    Shah, Gunjan L.
    Korde, Neha S.
    Roeker, Lindsey E.
    Mato, Anthony R.
    Batlevi, Connie L.
    Chung, David J.
    Doddi, Sital
    Falchi, Lorenzo
    Gyurkocza, Boglarka
    Hamilton, Audrey
    Lin, Ya-Hui
    Jakubowski, Ann A.
    Joffe, Erel
    Landau, Heather L.
    Lin, Richard J.
    Mailankody, Sham
    Palomba, M. Lia
    Park, Jae H.
    Perales, Miguel-Angel
    Ponce, Doris M.
    V. Ramanathan, Lakshmi
    Salles, Gilles A.
    Scordo, Michael
    Seo, Susan K.
    Shah, Urvi A.
    Stein, Eytan M.
    Straus, David
    Usmani, Saad Z.
    Young, James W.
    Zelenetz, Andrew D.
    Noy, Ariela
    Vardhana, Santosha A.
    CANCER CELL, 2022, 40 (06) : 590 - 591
  • [6] Resistance mutations in SARS-CoV-2 omicron variant after tixagevimab-cilgavimab treatment
    Vellas, Camille
    Kamar, Nassim
    Izopet, Jacques
    JOURNAL OF INFECTION, 2022, 85 (05) : E162 - E163
  • [7] Breakthrough SARS-CoV-2 infections among recipients of tixagevimab-cilgavimab prophylaxis: A citywide real-world effectiveness study
    Lendacki, Frances R.
    Li, Linda
    Forrest, Graeme N.
    Jordan, Leirah
    Zelinski, Christy
    Black, Stephanie R.
    Ison, Michael G.
    Seo, Jennifer Y.
    TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (01)
  • [8] Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination
    Callegari, Chiara
    Lazzarotto, Davide
    Soravia, Alessandra
    Mutti, Martina
    Lauzzana, Pietro
    Peghin, Maddalena
    Cordella, Stefano
    Fanin, Renato
    Candoni, Anna
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2023, 111 (04) : 668 - 670
  • [9] Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants
    Tuffy, Kevin M.
    Ahani, Bahar
    Aksyuk, Anastasia A.
    Avila, Miles
    Brady, Tyler
    Kijak, Gustavo H.
    Koh, Gavin
    Levin, Myron J.
    Roe, Tiffany L.
    Schuko, Nicolette
    Thissen, Jesse
    Ustianowski, Andrew
    Zhang, Tianhui
    Kelly, Elizabeth J.
    Streicher, Katie
    JOURNAL OF INFECTIOUS DISEASES, 2023, 228 (08): : 1055 - 1059
  • [10] Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov2 Variants in Patients with CLL
    Benjamini, Ohad
    Tadmor, Tamar
    Avigdor, Abraham
    Gershon, Rotem
    Klike, Limor
    Atari, Nofar
    Abdelkader, Bayan
    Mandelboim, Michal
    Rahav, Galia
    BLOOD, 2022, 140 : 9900 - 9901
12345